Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4441156
Max Phase: Preclinical
Molecular Formula: C51H73N10O25P
Molecular Weight: 1257.16
Molecule Type: Unknown
Associated Items:
ID: ALA4441156
Max Phase: Preclinical
Molecular Formula: C51H73N10O25P
Molecular Weight: 1257.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1cc(=O)oc2cc(OP(=O)(O)O)ccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C
Standard InChI: InChI=1S/C51H73N10O25P/c1-9-22(6)41(60-51(81)42(23(7)62)61-48(78)33(19-38(70)71)56-46(76)31(17-36(66)67)53-24(8)63)50(80)58-30(13-25-14-39(72)85-34-15-26(10-11-27(25)34)86-87(82,83)84)45(75)55-32(18-37(68)69)47(77)59-40(21(4)5)49(79)57-29(12-20(2)3)44(74)54-28(43(52)73)16-35(64)65/h10-11,14-15,20-23,28-33,40-42,62H,9,12-13,16-19H2,1-8H3,(H2,52,73)(H,53,63)(H,54,74)(H,55,75)(H,56,76)(H,57,79)(H,58,80)(H,59,77)(H,60,81)(H,61,78)(H,64,65)(H,66,67)(H,68,69)(H,70,71)(H2,82,83,84)/t22-,23+,28-,29-,30-,31-,32-,33-,40-,41-,42-/m0/s1
Standard InChI Key: USIAOGSKOJHRHX-MHLGECDUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1257.16 | Molecular Weight (Monoisotopic): 1256.4486 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ma ES, Barrios AM.. (2019) Rational design of a SHP-2 targeted, fluorogenic peptide substrate., 29 (17): [PMID:31351693] [10.1016/j.bmcl.2019.07.034] |
Source(1):